1. Home
  2. LGIH vs JANX Comparison

LGIH vs JANX Comparison

Compare LGIH & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$38.85

Market Cap

984.3M

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$14.94

Market Cap

790.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGIH
JANX
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
984.3M
790.3M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
LGIH
JANX
Price
$38.85
$14.94
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$75.90
$53.60
AVG Volume (30 Days)
597.2K
933.8K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.12
N/A
Revenue
$1,705,504,000.00
$10,000,000.00
Revenue This Year
$6.01
N/A
Revenue Next Year
$14.33
N/A
P/E Ratio
$12.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.55
$12.12
52 Week High
$69.42
$35.34

Technical Indicators

Market Signals
Indicator
LGIH
JANX
Relative Strength Index (RSI) 40.27 62.58
Support Level $33.55 $13.12
Resistance Level $41.50 $15.49
Average True Range (ATR) 2.22 0.54
MACD 0.51 0.13
Stochastic Oscillator 58.27 82.48

Price Performance

Historical Comparison
LGIH
JANX

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: